Literature DB >> 4026414

Tissue typing in brucellosis.

P T Dawes, S K Ghosh.   

Abstract

The index case in this report was clinically, epidemiologically, and serologically proved to be suffering from acute brucellosis acquired in Britain and complicated by acute intractable reactive arthritis. HLA tissue typing was A1, A2, B7, and B27. As there is no information available about HLA typing in brucellosis in Britain, we examined further cases of human brucellosis retrospectively. Three further patients possessing B27 antigen were identified, only one of whom had had reactive arthritis. Eight of the 12 cases studied also carried A2, which is thus shown not to be protective against the development of brucellosis as had been suggested previously.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4026414      PMCID: PMC1001695          DOI: 10.1136/ard.44.8.526

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  4 in total

Review 1.  HLA-B27 and the link with rheumatic diseases: recent developments.

Authors:  R W Ebringer
Journal:  Clin Sci (Lond)       Date:  1980-12       Impact factor: 6.124

2.  HLA-B27-associated spondylarthritis in chronic brucellosis.

Authors:  L Hodinka; B Gömör; K Merétey; Z Zahumenszky; P Géher; L Telegdy; S Bozsóky
Journal:  Lancet       Date:  1978-03-04       Impact factor: 79.321

3.  Antigenic analysis of different strains of Brucella.

Authors:  D V Joshi; O Prakash; G P Talwar
Journal:  Indian J Med Res       Date:  1971-08       Impact factor: 2.375

4.  The role of the laboratory in rheumatology. HLA antigens.

Authors:  P J Dewar
Journal:  Clin Rheum Dis       Date:  1983-04
  4 in total
  2 in total

1.  Tissue typing in brucellosis.

Authors:  T S Bocanegra; G S Alarcón; L R Espinoza
Journal:  Ann Rheum Dis       Date:  1986-04       Impact factor: 19.103

2.  Brucella arthritis: a study of 96 cases in Kuwait.

Authors:  M I Khateeb; G F Araj; S A Majeed; A R Lulu
Journal:  Ann Rheum Dis       Date:  1990-12       Impact factor: 19.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.